{"DataElement":{"publicId":"3124457","version":"1","preferredName":"Disease or Disorder Status International Neuroblastoma Response Criteria Type","preferredDefinition":"A description of the disease status based on the International Neuroblastoma Response Criteria.","longName":"2512861v1.0:3263657v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2512861","version":"1","preferredName":"Disease or Disorder Status","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A condition or state at a particular time.","longName":"2404658v1.0:2320064v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2404658","version":"1","preferredName":"Diseases and Disorders","preferredDefinition":"A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.","longName":"C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"005AD6E5-0651-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-09","endDate":null,"createdBy":"PWEST","dateCreated":"2005-09-09","modifiedBy":"ONEDATA","dateModified":"2005-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2320064","version":"1","preferredName":"Status","preferredDefinition":"A condition or state at a particular time.","longName":"C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC71B93E-037B-5AD9-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-25","modifiedBy":"ONEDATA","dateModified":"2005-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B898979-184A-3A90-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-21","endDate":null,"createdBy":"UMLLOADER_AGNIS","dateCreated":"2006-08-21","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3263657","version":"1","preferredName":"International Neuroblastoma Response Criteria Type","preferredDefinition":"A standard approach to aid in the stratification of neuroblastoma risk and disease evaluation._Type; a subdivision of a particular kind of thing.","longName":"3263657v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Not evaluable","valueDescription":"Unevaluable","ValueMeaning":{"publicId":"3153578","version":"1","preferredName":"Unevaluable","longName":"3153578","preferredDefinition":"Unable to be evaluated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unevaluable","conceptCode":"C62222","definition":"Unable to be evaluated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93AC689E-5DB2-5D7A-E040-BB89AD430948","latestVersionIndicator":"Yes","beginDate":"2010-10-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-10-28","modifiedBy":"KUMMEROA","dateModified":"2023-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB461F5D-3EF8-78CA-E040-BB89AD434E2B","beginDate":"2009-12-21","endDate":null,"createdBy":"SORENSENS","dateCreated":"2011-08-24","modifiedBy":"ONEDATA","dateModified":"2011-08-24","deletedIndicator":"No"},{"value":"Not tested / unknown","valueDescription":"Negation Test Or Unknown","ValueMeaning":{"publicId":"3262968","version":"1","preferredName":"Negation Test Or Unknown","longName":"3262968","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction.: A procedure for critical evaluation; a means of determining the presence, quality, or truth of something.: Or; used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.: Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Test","conceptCode":"C47891","definition":"A procedure for critical evaluation; a means of determining the presence, quality, or truth of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AAB93AED-F63B-381E-E040-BB89AD432C45","latestVersionIndicator":"Yes","beginDate":"2011-08-17","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-08-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B1C9C115-8CA4-6AED-E040-BB89AD43131A","beginDate":"2009-12-21","endDate":null,"createdBy":"NYCHM","dateCreated":"2011-11-15","modifiedBy":"ONEDATA","dateModified":"2011-11-15","deletedIndicator":"No"},{"value":"Mixed Response","valueDescription":"Mixed Response in Neuroblastoma","ValueMeaning":{"publicId":"5983744","version":"1","preferredName":"Mixed Response in Neuroblastoma","longName":"5983744","preferredDefinition":"Greater than 50% reduction of any measurable lesion (primary or metastases) with, less than 50% reduction in any other site; no new lesions; less than 25% increase in any existing lesion (exclude bone marrow evaluation).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mixed Response in Neuroblastoma","conceptCode":"C103315","definition":"Greater than 50% reduction of any measurable lesion (primary or metastases) with, less than 50% reduction in any other site; no new lesions; less than 25% increase in any existing lesion (exclude bone marrow evaluation).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5A1B4DE2-C139-087E-E053-F662850A40BA","latestVersionIndicator":"Yes","beginDate":"2017-09-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-09-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5A1B4DE2-C152-087E-E053-F662850A40BA","beginDate":"2017-09-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-09-26","modifiedBy":"ONEDATA","dateModified":"2017-09-26","deletedIndicator":"No"},{"value":"Minimal Response","valueDescription":"Minimal Response of Multiple Myeloma or Plasma Cell Leukemia","ValueMeaning":{"publicId":"3930091","version":"1","preferredName":"Minimal Response of Multiple Myeloma or Plasma Cell Leukemia","longName":"3930091","preferredDefinition":"Patients in whom some, but not all, the criteria for partial response are fulfilled are classified as minimal response (MR), provided the remaining criteria satisfy the requirements for minimal response.  MR requires all of the following: 1. 25-49% reduction in the level of the serum monoclonal paraprotein maintained for a minimum of 6 weeks; 2. 50-89% reduction in 24 h urinary light chain excretion, which still exceeds 200 mg/24 h, maintained for a minimum of 6 weeks; 3. for patients with non-secretory myeloma only, 25-49% reduction in plasma cells in a bone marrow aspirate and on trephine biopsy, if biopsy is performed, maintained for a minimum of 6 weeks; 4. 25-49% reduction in the size of soft tissue plasmacytomas (by radiography or clinical examination); 5. no increase in size or number of lytic bone lesions (development of a compression fracture does not exclude response) (adapted from National Comprehensive Cancer Network).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Minimal Response of Multiple Myeloma","conceptCode":"C111788","definition":"Patients in whom some, but not all, the criteria for partial response are fulfilled are classified as minimal response (MR), provided the remaining criteria satisfy the requirements for minimal response.  MR requires all of the following: 1. 25-49% reduction in the level of the serum monoclonal paraprotein maintained for a minimum of 6 weeks; 2. 50-89% reduction in 24 h urinary light chain excretion, which still exceeds 200 mg/24 h, maintained for a minimum of 6 weeks; 3. for patients with non-secretory myeloma only, 25-49% reduction in plasma cells in a bone marrow aspirate and on trephine biopsy, if biopsy is performed, maintained for a minimum of 6 weeks; 4. 25-49% reduction in the size of soft tissue plasmacytomas (by radiography or clinical examination); 5. no increase in size or number of lytic bone lesions (development of a compression fracture does not exclude response) (adapted from National Comprehensive Cancer Network).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E985AC3F-ADFA-797D-E040-BB89AD436957","latestVersionIndicator":"Yes","beginDate":"2013-10-24","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-10-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5C5DE9CD-02D0-19FA-E053-F662850AC0E9","beginDate":"2009-12-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-25","modifiedBy":"ONEDATA","dateModified":"2017-10-25","deletedIndicator":"No"},{"value":"No response","valueDescription":"No Response in Neuroblastoma","ValueMeaning":{"publicId":"6005228","version":"1","preferredName":"No Response in Neuroblastoma","longName":"6005228","preferredDefinition":"No new lesions; less than 50% reduction but less than 25% increase in any existing lesion (exclude bone marrow evaluation).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No Response in Neuroblastoma","conceptCode":"C103314","definition":"No new lesions; less than 50% reduction but less than 25% increase in any existing lesion (exclude bone marrow evaluation).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5BD24DDE-BE6C-7503-E053-F662850A73FA","latestVersionIndicator":"Yes","beginDate":"2017-10-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5BD24DDE-BE87-7503-E053-F662850A73FA","beginDate":"2009-12-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-18","modifiedBy":"ONEDATA","dateModified":"2017-10-18","deletedIndicator":"No"},{"value":"Complete response","valueDescription":"Complete Response in Neuroblastoma","ValueMeaning":{"publicId":"6005219","version":"1","preferredName":"Complete Response in Neuroblastoma","longName":"6005219","preferredDefinition":"No evidence of primary tumor, no evidence of metastases (chest, abdomen, liver, bone, bone marrow, nodes, etc.), and HVA/VMA normal.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete Response in Neuroblastoma","conceptCode":"C103312","definition":"No evidence of primary tumor, no evidence of metastases (chest, abdomen, liver, bone, bone marrow, nodes, etc.), and HVA/VMA normal.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5BD232CF-D9C2-0A3B-E053-F662850A6149","latestVersionIndicator":"Yes","beginDate":"2017-10-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5BD232CF-D9DD-0A3B-E053-F662850A6149","beginDate":"2009-12-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-18","modifiedBy":"ONEDATA","dateModified":"2017-10-18","deletedIndicator":"No"},{"value":"Partial response","valueDescription":"Partial Response in Neuroblastoma","ValueMeaning":{"publicId":"6005222","version":"1","preferredName":"Partial Response in Neuroblastoma","longName":"6005222","preferredDefinition":"Fifty to 90% reduction of primary tumor; 50% or greater reduction in measurable sites of metastases; 0-1 bone marrow samples with tumor; number of positive bone sites decreased by greater than 50%.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Partial Response in Neuroblastoma","conceptCode":"C103313","definition":"Fifty to 90% reduction of primary tumor; 50% or greater reduction in measurable sites of metastases; 0-1 bone marrow samples with tumor; number of positive bone sites decreased by greater than 50%.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5BD232CF-D9EA-0A3B-E053-F662850A6149","latestVersionIndicator":"Yes","beginDate":"2017-10-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5BD232CF-DA05-0A3B-E053-F662850A6149","beginDate":"2009-12-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-18","modifiedBy":"ONEDATA","dateModified":"2017-10-18","deletedIndicator":"No"},{"value":"Very good partial response","valueDescription":"Very Good Partial Response in Neuroblastoma","ValueMeaning":{"publicId":"6005225","version":"1","preferredName":"Very Good Partial Response in Neuroblastoma","longName":"6005225","preferredDefinition":"Greater than 90% reduction of primary tumor; no metastatic tumor (as above except bone); no new bone lesions, all pre-existing lesions improved on bone scan; HVA/VMA normal.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Very Good Partial Response in Neuroblastoma","conceptCode":"C103311","definition":"Greater than 90% reduction of primary tumor; no metastatic tumor (as above except bone); no new bone lesions, all pre-existing lesions improved on bone scan; HVA/VMA normal.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5BD232CF-DA12-0A3B-E053-F662850A6149","latestVersionIndicator":"Yes","beginDate":"2017-10-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5BD232CF-DA2D-0A3B-E053-F662850A6149","beginDate":"2009-12-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-18","modifiedBy":"ONEDATA","dateModified":"2017-10-18","deletedIndicator":"No"},{"value":"Progressive disease","valueDescription":"Progressive Disease in Neuroblastoma","ValueMeaning":{"publicId":"6010099","version":"1","preferredName":"Progressive Disease in Neuroblastoma","longName":"6010099","preferredDefinition":"Any component (i.e., soft tissue, bone, and bone marrow disease) with progressive disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progressive Disease in Neuroblastoma","conceptCode":"C140671","definition":"Any component (i.e., soft tissue, bone, and bone marrow disease) with progressive disease. (J Clin Oncol 35: 2580-2587, 2017)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5C496F8F-D7DD-68F1-E053-F662850AA7EF","latestVersionIndicator":"Yes","beginDate":"2017-10-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5C496F8F-D7F8-68F1-E053-F662850AA7EF","beginDate":"2009-12-21","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-24","modifiedBy":"ONEDATA","dateModified":"2017-10-24","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6005992","version":"1","preferredName":"International Neuroblastoma Response Criteria Type","preferredDefinition":"A standard approach to aid in the stratification of neuroblastoma risk and disease evaluation.:Something distinguishable as an identifiable class based on common qualities.","longName":"C102869:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"International Neuroblastoma Response Criteria","conceptCode":"C102869","definition":"A standard approach to aid in the stratification of neuroblastoma risk and disease evaluation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5BF97BBC-6DD9-442C-E053-F662850A544D","latestVersionIndicator":"Yes","beginDate":"2017-10-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-20","modifiedBy":"ONEDATA","dateModified":"2017-10-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB461F5D-3DC8-78CA-E040-BB89AD434E2B","latestVersionIndicator":"Yes","beginDate":"2009-12-21","endDate":null,"createdBy":"SORENSENS","dateCreated":"2011-08-24","modifiedBy":"KUMMEROA","dateModified":"2017-10-25","changeDescription":". Added concepts in for MC. AK 10/24/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2964894","version":"1","longName":"2026r1: Neuroblastoma Pre-HSCT Data","context":"NHLBI"},{"publicId":"3279271","version":"1","longName":"Disease Status","context":"NHLBI"}]},{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"neu_base_cur_dx_status_kn","type":"NMDP_FN","context":"NHLBI"},{"name":"PerformedDiagnosis:diseaseStatusCode","type":"HCT_BRIDG","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What was the disease status u","type":"Preferred Question Text","description":"What was the disease status using the International Neuroblastoma Response Criteria ?","url":null,"context":"NHLBI"},{"name":"BRIDG mapping for CDE:3124457","type":"BRIDG Mapping Path","description":"PerformedDiagnosis.diseaseStatusCode","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C48941D-24AB-12DA-E040-BB89AD435A12","latestVersionIndicator":"Yes","beginDate":"2010-07-26","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-07-26","modifiedBy":"KUMMEROA","dateModified":"2020-12-08","changeDescription":"2020-12-8 AK OK to release per WZ. System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}